Advertisement

International Journal of Hematology

, Volume 106, Issue 6, pp 852–859 | Cite as

Achievement of the longest survival of paraneoplastic pemphigus with bronchiolitis obliterans associated with follicular lymphoma using R-CHOP chemotherapy

  • Shin Lee
  • Takahiro Yamauchi
  • Norito Ishii
  • Takashi Hashimoto
  • Keiichi Kinoshita
  • Shin Imamura
  • Kenichi Kamiya
Case Report

Abstract

Paraneoplastic pemphigus (PNP) is a rare, fatal, paraneoplastic autoimmune mucocutaneous blistering disease, commonly associated with lymphoproliferative disorders, including malignant lymphomas. Lymphoproliferative disorders associated with PNP are sometimes associated with a serious lung complication, bronchiolitis obliterans (BO). Due to its rarity, guidelines for the management of PNP have not been established. Furthermore, most patients die within 1 year. Here we report the successful treatment of lymphoma-associated PNP and BO using R-CHOP chemotherapy. A 53-year-old Japanese man was admitted to our hospital for severe erosive stomatitis. Computed tomography and positron emission tomography showed multiple lymphadenopathies. He was diagnosed with follicular lymphoma (Ann Arbor stage IVA) and PNP-related BO. The patient underwent six cycles of R-CHOP and an additional cycle of rituximab. Both the erosive stomatitis and the obstructive lung disease persisted, but complete response of the follicular lymphoma was achieved. The patient survived 27 months after diagnosis. Although he died from progressive respiratory failure due to BO, we note that this patient achieved the longest survival of any reported case of PNP-related BO associated with a lymphoproliferative disorder. The present case suggests that intensive immunochemotherapy for underlying lymphoma may improve the prognosis in patients with PNP-related BO associated with lymphoma.

Keywords

R-CHOP Follicular lymphoma Paraneoplastic pemphigus Bronchiolitis obliterans 

Notes

Acknowledgements

The authors wish to acknowledge Dr. K. Takeuchi and Dr. M. Ohta for their scientific advice. The first author would like to thank her husband, Dr. T. Morishita, for useful discussion.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Anhalt GJ, Kim SC, Stanley JR, Korman NJ, Jabs DA, Kory M, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med. 1990;323:1729–35.CrossRefPubMedGoogle Scholar
  2. 2.
    Nguyen VT, Ndoye A, Bassler KD, Shults LD, Shields MC, Ruben BS, et al. Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: a reappraisal of paraneoplastic pemphigus. Arch Dermatol. 2001;137:193–206.PubMedGoogle Scholar
  3. 3.
    Oursler JR, Labib RS, Ariss-Abdo L, Burke T, O’keefe EJ, Anhalt GJ, et al. Human autoantibodies against desmoplakins in paraneoplastic pemphigus. J Clin Investig. 1992;89:1775–82.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Hashimoto T, Amagai M, Watanabe K, Chorzelski TP, Black MM, Stevens HP, et al. Characterization of paraneoplastic pemphigus autoantigens by immunoblot analysis. J Investig Dermatol. 1995;104:829–34.CrossRefPubMedGoogle Scholar
  5. 5.
    Frew JW, Murrell DF. Current management strategies in paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome). Dermatol Clin. 2011;29:419–25.CrossRefPubMedGoogle Scholar
  6. 6.
    Leger S, Picard D, Ingen-Housz-Oro S, Arnault JP, Aubin F, Carsuzaa F, et al. Prognostic factors of paraneoplastic pemphigus. Arch Dermatol. 2012;148:1165–72.CrossRefPubMedGoogle Scholar
  7. 7.
    Animesh A. Paraneoplastic pemphigus: autoimmune-cancer nexus in the skin. Anticancer Agents Med Chem. 2015;15:1215–23.CrossRefGoogle Scholar
  8. 8.
    Sehgal VN, Srivastava G. Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome. Int J Dermatol. 2009;48:162–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Nousari HC, Deterding R, Wojtczack H, Aho S, Uitto J, Hashimoto T, et al. The mechanism of respiratory failure in paraneoplastic pemphigus. N Engl J Med. 1999;340:1406–10.CrossRefPubMedGoogle Scholar
  10. 10.
    Maldonado F, Pittelkow MR, Ryu JH. Constrictive bronchiolitis associated with paraneoplastic autoimmune multi-organ syndrome. Respirology. 2009;14:129–33.CrossRefPubMedGoogle Scholar
  11. 11.
    Nikolskaia OV, Nousari CH, Anhalt GJ. Paraneoplastic pemphigus in association with Castleman’s disease. Br J Dermatol. 2003;149:1143–51.CrossRefPubMedGoogle Scholar
  12. 12.
    Joly P, Richard C, Gilbert D, Couville P, Chosidow O, Roujeau JC, et al. Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol. 2000;43:619–26.CrossRefPubMedGoogle Scholar
  13. 13.
    Meyer KC, Raghu G, Verleden GM, Corris PA, Aurora P, Wilson KC, et al. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. Eur Respir J. 2014;44:1479–503.CrossRefPubMedGoogle Scholar
  14. 14.
    Anderson KM, Smith P, Norton A, Hancock BW, Hoskin PJ, MacLennan KA, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomized controlled trial. Lancet. 2003;362:516–22.CrossRefGoogle Scholar
  15. 15.
    Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P, et al. Comparison in low-tomor-burden follicular lymphoma between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Group d’Etude des Lymphomes Folliculares. J Clin Oncol. 1997;15:1110–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Solal-Celigny P, Lepage E, Brousse N, Tendler CL, Brice P, Haioun C, et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Group d’Etude des Lymphomes Folliculares 86 trial. J Clin Oncol. 1998;16:2332–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Ohzono A, Sogame R, Li X, Teye K, Tsuchiasaka A, Numata S, et al. Clinical immunological findings in 104 cases of paraneoplastic pemphigus. Br J Dermatol. 2015;173:1447–52.CrossRefPubMedGoogle Scholar
  18. 18.
    Kaplan I, Hodak E, Ackerman L, Mimouni D, Calderon S. Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations. Oral Oncol. 2004;40:553–62.CrossRefPubMedGoogle Scholar
  19. 19.
    Hirano T, Higuchi Y, Yuki H, Hirata S, Nosaka K, Ishii N, et al. Rituximab monotherapy and rituximab-containing chemotherapy were effective for paraneoplastic pemphigus accompanying follicular lymphoma, but not for subsequent bronchiolitis obliterans. J Clin Exp Hematol. 2015;55:83–8.CrossRefGoogle Scholar
  20. 20.
    Hoffman MA, Qiao X, Anhalt GJ. CD8+ T lymphocytes in bronchiolitis obliterans, paraneoplastic pemphigus, and solitary Castleman’s disease. N Engl J Med. 2003;349:407–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Chang JM, Lee HJ, Goo JM, Lee HY, Lee JJ, Chung JK, et al. False positive and false negative FDG-PET scans in various thoracic diseases. Korean J Radiol. 2006;7:57–9.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Estenne M, Hertz MI. Bronchiolitis obliterans after human lung transplantation. Am J Respir Crit Care. 2002;16:440–4.CrossRefGoogle Scholar
  23. 23.
    Tateishi U, Hasegawa T, Terauchi T, Moriyama N, Arai Y. Disease activity and 18F-FDG uptake in organizing pneumonia: semi-quantitative evaluation using computed tomography and position emission tomography. Eur J Nucl Med Mol Imaging. 2006;33:906–12.CrossRefPubMedGoogle Scholar
  24. 24.
    Takahashi M, Shimatsu Y, Kazama T, Kimura K, Otuka T, Hashimoto T, et al. Paraneoplastic pemphigus associated with bronchiolitis obliterans. Chest. 2000;117:603–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Gudi VS, Ormerod AD, Weir J, Kerr KM, Devereux G. Severe breathlessness, mouth ulcers and skin blistering in a female. Eur Respir J. 2004;24:884–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Wang SH, Chu CY, Chen HH, Chang YL, Chen KY, Chiu HC, et al. Paraneoplastic pemphigus and bronchiolitis obliterans in a patient with splenic B-cell lymphoma. J Formos Med Assoc. 2007;106:768–73.CrossRefPubMedGoogle Scholar
  27. 27.
    Park KY, Choi SY, Seo SJ, Hong CK. Case or paraneoplastic pemphigus associated with retroperitoneal diffuse large B-cell lymphoma and fetal bronchiolitis obliterans-like lung disease. J Dermatol. 2013;40:142–4.CrossRefGoogle Scholar
  28. 28.
    Kanaoka M, Matsukura S, Ishikawa H, Matsuura M, Ishii N, Hashimoto T, et al. Paraneoplastic pemphigus associated with fetal bronchiolitis obliterans and appearance of anti-BP180 antibodies in the late stage of the disease. J Dermatol. 2014;41:628–30.CrossRefPubMedGoogle Scholar
  29. 29.
    Morikawa K, Tsuji T, Yamasaka H, Egashira S, Kaguchi A, Kido M, et al. Paraneoplastic pemphigus occurs most commonly in indolent B call lymphoma. Acta Haematol. 2014;132:73–4.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2017

Authors and Affiliations

  • Shin Lee
    • 1
  • Takahiro Yamauchi
    • 2
  • Norito Ishii
    • 3
  • Takashi Hashimoto
    • 4
  • Keiichi Kinoshita
    • 1
  • Shin Imamura
    • 1
  • Kenichi Kamiya
    • 1
  1. 1.Department of HematologyJapan Red Cross Fukui HospitalFukuiJapan
  2. 2.Department of Hematology and Oncology, Faculty of Medical SciencesUniversity of FukuiFukuiJapan
  3. 3.Department of Dermatology, School of MedicineKurume UniversityFukuokaJapan
  4. 4.Kurume University Institute of Cutaneous Cell BiologyFukuokaJapan

Personalised recommendations